Mankind Pharma incorporates wholly owned subsidiary in Netherlands

Strategic Transactions View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹2404.40

prior close

₹2412.50

announcement price

After-mkt

timing

Nifty Midcap 150market-0.5%+1.4% vs market

Pharmaceuticals peers, median of 166sector-0.4%+1.3% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Midcap 150 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+1.3

15m

+0.7

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9-0.5+1.4-0.4+1.3

Next day

-1.0-0.4-0.6-0.3-0.6

-1.0-0.7-0.3-0.5-0.5

-0.4-1.0+0.6-1.4+1.0

-0.8-0.6-0.2-0.9+0.1

-0.8-0.6-0.3-0.4-0.5

-1.8-0.0-1.7-0.9-0.9

15d

-3.2-1.6-1.6+0.0-3.3

-5.2-5.0-0.1-0.1-5.1

-2.9-7.3+4.4-2.6-0.2

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma has incorporated a wholly owned subsidiary named Mankind Pharma (Netherlands) B.V. in the Netherlands on August 13, 2026. This follows an earlier intimation dated July 11, 2026. Detailed disclosures on the subsidiary were already shared in the prior filing.

Likely market impact

Signals overseas expansion plans. Likely minimal immediate financial impact; builds on prior July 2026 intimation.